UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 702

Sortiert nach

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Annals of oncology, 2019-04, Vol.30 (4), p.551-557

2019

Volltextzugriff (PDF)

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Volltextzugriff (PDF)

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Annals of oncology, 2019-07, Vol.30 (7), p.1080-1087

2019

Volltextzugriff (PDF)

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

British journal of cancer, 2013-04, Vol.108 (6), p.1231-1237

2013

Volltextzugriff (PDF)

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i4-i10

2016

Volltextzugriff (PDF)

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Annals of oncology, 2017-03, Vol.28 (3), p.512-518

2017

Volltextzugriff (PDF)

Understanding the effect of mechanical forces on ovarian cancer progression

Gynecologic oncology, 2021-07, Vol.162 (1), p.154-162

2021

Volltextzugriff (PDF)

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Annals of oncology, 2018-04, Vol.29 (4), p.917-923

2018

Volltextzugriff (PDF)

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2124-2130

2016

Volltextzugriff (PDF)

Ovarian cancer: genomic analysis

Annals of oncology, 2013-12, Vol.24 Suppl 10 (suppl_10), p.x7-x15

2013

Volltextzugriff (PDF)

How can molecular abnormalities influence our clinical approach

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii16-viii24

2017

Volltextzugriff (PDF)

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Gynecologic oncology, 2018-02, Vol.148 (2), p.275-280

2018

Volltextzugriff (PDF)

RASSF6 is a novel member of the RASSF family of tumor suppressors

Oncogene, 2007-09, Vol.26 (42), p.6203-6211

2007

Volltextzugriff (PDF)

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Annals of oncology, 2018-10, Vol.29, p.viii339-viii339

2018

Volltextzugriff (PDF)

Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis

The Journal of biological chemistry, 2000-11, Vol.275 (46), p.35669-35672

2000

Volltextzugriff (PDF)

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Gynecologic oncology, 2019-05, Vol.153 (2), p.223-229

2019

Volltextzugriff (PDF)

Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling

Oncogene, 2007-03, Vol.26 (13), p.1971-1982

2007

Volltextzugriff (PDF)

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis

Oncogene, 2014-08, Vol.33 (35), p.4424-4432

2014

Volltextzugriff (PDF)

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

Annals of oncology, 2018-10, Vol.29, p.viii728-viii728

2018

Volltextzugriff (PDF)

Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

Nature (London), 1996-03, Vol.380 (6569), p.75-79

1996

Volltextzugriff (PDF)

Identification of LMX1B as a novel oncogene in human ovarian cancer

Oncogene, 2014-08, Vol.33 (33), p.4226-4235

2014

Volltextzugriff (PDF)

An in situ cell to study phase transitions in individual aerosol particles on a substrate using scanning transmission x-ray microspectroscopy

Review of scientific instruments, 2010-11, Vol.81 (11), p.113706-113706-9

2010

Volltextzugriff (PDF)

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer

Gynecologic oncology, 2016-04, Vol.141 (1), p.108-112

2016

Volltextzugriff (PDF)

Retraction of the mobile descended larynx during groaning enables fallow bucks (Dama dama) to lower their formant frequencies

Journal of zoology (1987), 2006-10, Vol.270 (2), p.340-345

2006

Volltextzugriff (PDF)

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

Oncogene, 1999-10, Vol.18 (44), p.6063-6070

1999

Volltextzugriff (PDF)

1 – 25 von 702

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(657)
Mit Volltextzugriff
(652)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Understanding the effect of mechanical forces on ovarian cancer progression

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Ovarian cancer: genomic analysis

How can molecular abnormalities influence our clinical approach

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

RASSF6 is a novel member of the RASSF family of tumor suppressors

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study

Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin

Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

Identification of LMX1B as a novel oncogene in human ovarian cancer

An in situ cell to study phase transitions in individual aerosol particles on a substrate using scanning transmission x-ray microspectroscopy

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer

Retraction of the mobile descended larynx during groaning enables fallow bucks (Dama dama) to lower their formant frequencies

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

Suchergebnisse filtern